↓ Skip to main content

Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety

Overview of attention for article published in Drug Design, Development and Therapy, November 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

policy
1 policy source
twitter
10 X users

Citations

dimensions_citation
49 Dimensions

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety
Published in
Drug Design, Development and Therapy, November 2014
DOI 10.2147/dddt.s73428
Pubmed ID
Authors

Dongsheng Hong, Zhihai Yang, Shuyin Han, Xingguang Liang, Kuifen Ma, Xingguo Zhang

Abstract

Anakinra is the first interleukin-1 inhibitor to be used in clinical practice, and recent evidence showed that interleukin-1 plays a pivotal role in the pathogenesis of adult-onset Still disease (AoSD). However, data concerning efficacy with anakinra use in different clinical trials has not been evaluated, and the overall remission of AoSD with anakinra treatment has not been well defined.

X Demographics

X Demographics

The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 15%
Student > Postgraduate 5 13%
Student > Master 5 13%
Student > Doctoral Student 4 10%
Student > Ph. D. Student 4 10%
Other 8 21%
Unknown 7 18%
Readers by discipline Count As %
Medicine and Dentistry 15 38%
Pharmacology, Toxicology and Pharmaceutical Science 4 10%
Agricultural and Biological Sciences 3 8%
Neuroscience 3 8%
Immunology and Microbiology 1 3%
Other 2 5%
Unknown 11 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 August 2022.
All research outputs
#3,789,447
of 25,374,917 outputs
Outputs from Drug Design, Development and Therapy
#248
of 2,268 outputs
Outputs of similar age
#43,146
of 273,831 outputs
Outputs of similar age from Drug Design, Development and Therapy
#12
of 53 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,831 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.